CareFusion Expands Specialty Disposables Business with Acquisition from GE Healthcare - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CareFusion Expands Specialty Disposables Business with Acquisition from GE Healthcare


CareFusion has signed a definitive agreement to acquire the Vital Signs division of GE Healthcare for $500 million, CareFusion announced in a press release. Vital Signs manufactures single-patient-use consumables for respiratory care and anesthesiology. The acquisition will expand CareFusion's Specialty Disposables business by adding global scale and new products for anesthesiology.

CareFusion expects the acquisition to advance its goal of expanding in international markets. The acquisition will accelerate the transformation of the Specialty Disposables business from a distributor to a vertically integrated manufacturer. With the addition of the Vital Signs portfolio, CareFusion will become a full-line provider of more than 20,000 single-use consumables for respiratory care and anesthesiology, including circuits for oxygen and anesthesia, humidification, masks, filters, pressure infusers, and temperature-management products.

The acquisition is expected to be completed for the Vital Signs business in the United States, China and certain other countries by Dec. 31, 2013. The company expects to finalize the remainder of the transaction during its third quarter, ending March 31, 2014, subject to regulatory review and customary closing conditions. Headquartered in Totowa, New Jersey, Vital Signs has more than 1000 employees in three primary locations worldwide, including manufacturing operations in Shenzhen, China, and a global, field-based sales organization.

Source: CareFusion


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here